CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer –– Q3 2025 ending cash, cash equivalents and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback